Overview
Grifols is one of the leading global specialty plasma therapeutics companies developing, manufacturing, and distributing a broad range of biological medicines based on plasma derived proteins. Founded in 1909, its products and services are used by healthcare providers in over 100 countries to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. It also has built a diagnostic
...
Read More business that focuses on researching, developing, manufacturing and marketing in vitro diagnostics products for use in clinical and blood bank laboratories. In addition, it also specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. Most of its revenue was generated outside of its home country, Spain.
Read Less
Read More business that focuses on researching, developing, manufacturing and marketing in vitro diagnostics products for use in clinical and blood bank laboratories. In addition, it also specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. Most of its revenue was generated outside of its home country, Spain.
Read Less
BERNER, ANNE-CATHERINE
See more contacts
Management of Companies and Enterprises
,
Holding companies, nec
?
?
Actual
$7.63 billion
Actual
9.41%
270.81%
$21,405
DEC
?
?
Spanish:GRF
Contacts
Get in Touch with 29 Principals*
-
BERNER, ANNE-CATHERINEPresident
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$7.63 billion
USD
Actual
1 USD = 0.9456 EUR
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $954 | $231 | -$2 |
| Net Investing Cash | $938 | -$417 | -$2,111 |
| Net Financing Cash | -$1,437 | $181 | -$174 |
| Net Change in Cash | $455 | -$5 | -$2,287 |
| Cash at Beginning of Period | $560 | $581 | $2,830 |
| Cash at End of Period | $1,036 | $560 | $581 |
| Capital Expenditure | -$393 | -$328 | -$415 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1,036 | $560 | $581 |
| Accounts Receivable | $746 | $682 | $644 |
| Inventories | $3,765 | $3,683 | $3,422 |
| Other Current Assets | $510 | $1,559 | $313 |
| Asset Summary | |||
| Total Current Assets | $6,057 | $6,484 | $4,960 |
| Tangible Fixed Assets | $4,558 | $4,433 | $4,530 |
| Intangible Assets | $3,094 | $2,995 | $3,119 |
| Total Assets | $21,405 | $20,992 | $21,230 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $901 | $870 | $833 |
| Short-Term Debt | $553 | $931 | $ |
| Other Current Liabilities | $826 | $657 | $1,302 |
| Liability Summary | |||
| Total Current Liabilities | $2,280 | $2,459 | $2,135 |
| Long-Term Debt | $8,905 | $9,497 | $ |
| Other Long-Term Liabilities | $48 | $51 | $10,654 |
| Total Liabilities | $13,534 | $14,254 | $14,016 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $126 | $126 | $126 |
| Retained Earnings | $166 | $45 | $ |
| Equity Summary | |||
| Total Equity | $6,222 | $5,677 | $5,973 |
| Shares Outstanding | 680,409,104 | 679,092,279 | 678,410,694 |